HI-Bio: A Biogen Company’s Post

Click here for the full content: https://bit.ly/CT-801794 On Thursday, October 26, #BMS held its Q3 2023 earnings call (press release: https://bit.ly/45Q0jCk / presentation: https://bit.ly/47aufKr) disclosing a significant revenue decrease for #Abecma (#BCMA CAR-T) and a decline in #Breyanzi (#CD19 CAR-T) sales. Additionally, BMS confirmed the dosing of the first patient in the Ph1 trial evaluating BMS-986353 (CC-97540; CD19 NEX-T CAR-T) in severe refractory systemic lupus erythematosus (#SLE), while announcing IND clearance from the #FDA to start a trial in multiple sclerosis (#MS). Celltelligence provides insights on the potential causes behind the Abecma and Breyanzi sales drops while discussing the initiation of the Ph3 KarMMa-9 trial in #NDMM and BMS’s fast progress in the #autoimmune disease space.

This #AutoimmuneDiseaseAwarenessMonth, learn how plasmacytoid dendritic cells (pDCs), can play a key role in many autoimmune diseases like lupus, dermatomyositis, and more. 🔬 Amgen is moving science forward for patients who need treatment options that target drivers of disease. 🔗 https://amgen.ly/3v72hlP

ASH 2023: Achieving long-term remission in autoimmune diseases such as systemic lupus erythematosus (SLE), idiopathic inflammatory myositis (IIM), and systemic sclerosis (SSc) is challenging and often requires prolonged treatment courses with varying success. In this MEDtalk, Dr. Mueller will discuss the challenges these severe autoimmune diseases present and how CD19 CAR T-cells offer a potential treatment where other therapies have failed. With a focus on the impressive data from their treatments, including complete remission in all patients and the intriguing biological aspects of the therapy, this video is set to provide in-depth insights into the future of autoimmune disease treatment. See all available ASH content here: https://lnkd.in/ewFP2hPn #SLE #IIM #SSc #ASH23

Did you know? Pompe disease is a severe genetic disorder. Even if treated, those with infant-onset Pompe rarely survive beyond early childhood. The current standard treatment, enzyme replacement therapy (ERT), can extend life expectancy into adolescence. However, ERT has significant shortcomings. It does not target skeletal muscle effectively, leading to progressive muscle weakness and respiratory issues over time. Moreover, ERT requires lifelong bi-weekly infusions, which can be burdensome for patients and families.   There is an urgent unmet need for more efficient therapies that can provide better disease management, improve quality of life, and extend survival. At Sutura Therapeutics, we're committed to addressing this unmet need by developing targeted treatments that significantly improve outcomes for patients with this severe disease.   Follow us to learn more about our efforts and the latest developments in Pompe disease research.   #PompeDisease #RareDiseases #HealthcareInnovation #FightRareDiseases

The LIVERAIM project, A Biomarker-Based Platform for Early Diagnosis of Chronic Liver Disease to Enable Personalized Therapy, started on 3 March, 2024, and will last until 28 February, 2030. https://lnkd.in/dcuK-C9p The aim of the project is to identify liver disease early and apply personalized therapy. #liveraim #projekt #MEFZg #medicinskifakultet

I hope you are all enjoying the Healing from Lyme Disease Summit. We are into a day two with great talks on mitochondrial function (Garth Nicolson and Ari S), healing with dapsone combination therapy with Dr H (Ali's story for those who missed the documentary yesterday); Joe Burrascano is discussing how to navigate the difficulties with chronic Lyme; Felix S is discussing the role of T cell testing in Lyme and co-infections when standard testing may be negative; Rachel and Dorothy Leland discuss their families journey through diagnosing and treating CLD (great stories); Dan Cameron is discussing treatment controversies; Nafysa P is discussing the root causes of illness in CLD; and finally I am discussing personalizing Lyme protocols, which is essential in getting patients better. This Summit is very comprehensive, and our 40-50 experts are providing the most up-to-date scientific knowledge on how to heal from Lyme. Please consider purchasing a copy of this Summit, or giving it as a gift, as the 90 minute dapsone Documentary and several talks that I have done on how to safely and effectively use dapsone, is providing essential information for providers and patients. Every day I am having more and more success with this protocol, and I wish to share it with the world so everyone can access this important knowledge that is getting my patients better. Yours in Health, Rich Horowitz

ASH 2023: Achieving long-term remission in autoimmune diseases such as systemic lupus erythematosus (SLE), idiopathic inflammatory myositis (IIM), and systemic sclerosis (SSc) is challenging and often requires prolonged treatment courses with varying success. In this MEDtalk, Dr. Mueller will discuss the challenges these severe autoimmune diseases present and how CD19 CAR T-cells offer a potential treatment where other therapies have failed. With a focus on the impressive data from their treatments, including complete remission in all patients and the intriguing biological aspects of the therapy, this video is set to provide in-depth insights into the future of autoimmune disease treatment. See all available ASH content here: https://lnkd.in/ePnc9jS9 #SLE #IIM #SSc #ASH23

ASH 2023: Achieving long-term remission in autoimmune diseases such as systemic lupus erythematosus (SLE), idiopathic inflammatory myositis (IIM), and systemic sclerosis (SSc) is challenging and often requires prolonged treatment courses with varying success. In this MEDtalk, Dr. Mueller will discuss the challenges these severe autoimmune diseases present and how CD19 CAR T-cells offer a potential treatment where other therapies have failed. With a focus on the impressive data from their treatments, including complete remission in all patients and the intriguing biological aspects of the therapy, this video is set to provide in-depth insights into the future of autoimmune disease treatment. See all available ASH content here: https://lnkd.in/ewFP2hPn #SLE #IIM #SSc #ASH23

Did you know that LIVERFASt and VCTE outperformed ELF for staging advanced liver fibrosis? In one of our recent studies, we compared different noninvasive methods (NIMs) - LIVERFASt, liver stifness measurement (LSM) with transient elastography (TE, Fibroscan), ELF and FiB-4 - in a prospective cohort with chronic liver diseases (CLD) from a tertiary liver center. The study concluded that LIVERFASt and VCTE outperformed ELF for staging advanced liver fibrosis. Read more about it here: https://lnkd.in/digzt5Vg #Fibronostics #healthmatters #NoninvasiveDiagnostics #DigitalHealthcare #MetabolicDiseases #livediseasediagnosis #LIVERFASt #newtechnology #noninvasivetesting #DigestivePathology #DigestiveHealth #fattyliver #fattyliverprevention

Autoimmune arthritis encompasses a range of conditions where the body's immune system mistakenly attacks its own joints, causing pain, swelling, and reduced mobility. At Oncquest, we are dedicated to providing advanced diagnostic solutions to aid in the early detection and management of autoimmune arthritis. Early diagnosis can make a significant difference in the quality of life for those affected. Let's join hands to support patients and advocate for more research and better treatment options. Together, we can make a difference! Discover more about our specialized tests and services for autoimmune diseases at Oncquest Laboratories. Book your test now https://lnkd.in/dYBhupDz #AutoimmuneArthritisDay #OncquestLabs #HealthcareHeroes #AutoimmuneAwareness #EarlyDiagnosis #TogetherWeCan #oncquest #oncquestlabs